MedTrace Logo

Reboxetine Adjuvant Therapy for the Treatment of Schizophrenia

NCT00409201 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2006-12-08

No results posted yet for this study

Summary

30 patients will randomly be selected and will be administered either reboxetine or a placebo. changes in cognition and behavior will be assessed by computer tests and scales during a six week study period.

Conditions

Interventions

DRUG

reboxetine adjuvant therapy

Sponsors & Collaborators

  • Abarbanel Mental Health Center

    lead OTHER_GOV

Principal Investigators

  • stanislav baranchik, md · abarbanel mhc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Completion
2006-11-30

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00409201 on ClinicalTrials.gov